mitoxantrone
E852340
anthracenedione
antineoplastic agent
chemotherapeutic agent
immunosuppressive agent
topoisomerase II inhibitor
Mitoxantrone is an anthracenedione chemotherapeutic agent used primarily to treat certain cancers and multiple sclerosis by intercalating DNA and inhibiting topoisomerase II.
All labels observed (1)
| Label | Occurrences |
|---|---|
| mitoxantrone canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10291876 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: mitoxantrone Context triple: [BCRP, substrateOf, mitoxantrone]
-
A.
vincristine
Vincristine is a chemotherapy medication, specifically a vinca alkaloid, widely used in combination regimens to treat various cancers including lymphomas and leukemias.
-
B.
cyclophosphamide
Cyclophosphamide is a widely used alkylating chemotherapy and immunosuppressive drug commonly employed in the treatment of cancers and autoimmune diseases.
-
C.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
D.
docetaxel
Docetaxel is a chemotherapy drug in the taxane class used to treat various cancers, including breast, lung, prostate, and gastric cancers, by inhibiting cell division.
-
E.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: mitoxantrone Target entity description: Mitoxantrone is an anthracenedione chemotherapeutic agent used primarily to treat certain cancers and multiple sclerosis by intercalating DNA and inhibiting topoisomerase II.
-
A.
vincristine
Vincristine is a chemotherapy medication, specifically a vinca alkaloid, widely used in combination regimens to treat various cancers including lymphomas and leukemias.
-
B.
cyclophosphamide
Cyclophosphamide is a widely used alkylating chemotherapy and immunosuppressive drug commonly employed in the treatment of cancers and autoimmune diseases.
-
C.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
D.
docetaxel
Docetaxel is a chemotherapy drug in the taxane class used to treat various cancers, including breast, lung, prostate, and gastric cancers, by inhibiting cell division.
-
E.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
anthracenedione
ⓘ
antineoplastic agent ⓘ chemotherapeutic agent ⓘ immunosuppressive agent ⓘ topoisomerase II inhibitor ⓘ |
| approvedBy | US Food and Drug Administration NERFINISHED ⓘ |
| bindsTo | DNA ⓘ |
| developedBy | Lederle Laboratories NERFINISHED ⓘ |
| hasAdverseEffect |
alopecia
ⓘ
amenorrhea ⓘ cardiotoxicity ⓘ congestive heart failure ⓘ myelosuppression ⓘ nausea ⓘ secondary leukemia ⓘ vomiting ⓘ |
| hasApprovalFor | multiple sclerosis (US, restricted use) ⓘ |
| hasATCCode |
L01DB07
ⓘ
L04AX07 ⓘ |
| hasBlackBoxWarning |
cardiotoxicity
ⓘ
secondary acute myeloid leukemia ⓘ |
| hasCASNumber | 65271-80-9 ⓘ |
| hasChemicalFormula | C22H28N4O6 ⓘ |
| hasColor | blue ⓘ |
| hasEliminationHalfLife | about 8–15 days ⓘ |
| hasIUPACName | 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione ⓘ |
| hasMolarMass | 444.48 g/mol ⓘ |
| hasOrigin | synthetic compound ⓘ |
| hasPregnancyCategory | D (US, historical) ⓘ |
| hasRisk | cumulative dose–dependent cardiotoxicity ⓘ |
| inhibits | topoisomerase II ⓘ |
| isAdministeredAs | mitoxantrone hydrochloride ⓘ |
| isContraindicatedIn |
baseline severe cardiac dysfunction
ⓘ
severe hepatic impairment ⓘ |
| isExcretedVia |
bile
ⓘ
feces ⓘ urine ⓘ |
| isMetabolizedBy | hepatic pathways ⓘ |
| isTeratogenic | true ⓘ |
| mechanismOfAction |
DNA intercalation
ⓘ
topoisomerase II inhibition ⓘ |
| routeOfAdministration | intravenous ⓘ |
| usedForTreatmentOf |
acute myeloid leukemia
ⓘ
metastatic breast cancer ⓘ multiple sclerosis ⓘ non-Hodgkin lymphoma NERFINISHED ⓘ progressive relapsing multiple sclerosis ⓘ prostate cancer ⓘ secondary progressive multiple sclerosis ⓘ worsening relapsing-remitting multiple sclerosis ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: mitoxantrone Description of subject: Mitoxantrone is an anthracenedione chemotherapeutic agent used primarily to treat certain cancers and multiple sclerosis by intercalating DNA and inhibiting topoisomerase II.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.